Clinical Trials Logo

Filter by:
NCT ID: NCT01437735 Completed - Asthma Clinical Trials

Dose Finding Study for QAW039 in Asthma

Start date: August 2011
Phase: Phase 2
Study type: Interventional

This study aims to demonstrate a clinically significant improvement in Forced Expiratory Volume in one second (FEV1) in moderate to severe allergic asthmatics inadequately controlled by Inhaled Corticosteroid (ICS) therapy. Patients will be treated with QAW039, an active comparator, or placebo. This will be a randomized, placebo-controlled, dose-ranging, multi-centre trial.

NCT ID: NCT01437657 Completed - Clinical trials for Major Depressive Disorder

MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

Start date: October 2011
Phase: Phase 2
Study type: Interventional

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing antidepressant therapy. Anticipated time on study treatment is 6 weeks with a 3-week follow-up.

NCT ID: NCT01437098 Completed - Clinical trials for Aortic Valve Stenosis

Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic Stenosis

Start date: October 2011
Phase: N/A
Study type: Interventional

The primary objective of the present trial is to demonstrate the effectiveness and safety of the MDT-2111 in the treatment of symptomatic severe aortic stenosis in subjects deemed difficult for surgical operation.

NCT ID: NCT01436656 Completed - Clinical trials for Melanoma and Metastatic Colorectal Cancer

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Start date: September 5, 2011
Phase: Phase 1
Study type: Interventional

CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily and/or every-other-day), a RAF kinase inhibitor. Patients with locally advanced or metastatic melanoma harboring the BRAF V600 mutation (during dose escalation phase and expansion phase) and patients with metastatic colorectal cancer harboring the BRAF V600 mutation (during the expansion phase) will be enrolled. The study consists of a dose escalation part were cohorts of patients will receive escalating oral doses of LGX818, followed by a safety dose expansion part were patients will be treated with oral dose of LGX818 given at the MTD or RP2D.

NCT ID: NCT01436513 Completed - Menopause Clinical Trials

A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.

Start date: October 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the bioequivalence and food effect for a new Premarin formulation compared with a Premarin reference tablet in Japanese healthy postmenopausal women.

NCT ID: NCT01435863 Completed - Clinical trials for Peripheral T-cell Lymphoma

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)

Start date: September 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Japanese patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).

NCT ID: NCT01435655 Completed - Clinical trials for Transthyretin Familial Amyloid Polyneuropathy

The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin

Start date: November 2011
Phase: Phase 3
Study type: Interventional

Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.

NCT ID: NCT01435629 Completed - Achondroplasia Clinical Trials

A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin

Start date: November 22, 2012
Phase: N/A
Study type: Observational

This study is conducted in Japan. The aim of the study is to evaluate the efficacy of somatropin (Norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the GH-1941 study (NCT01516229).

NCT ID: NCT01435525 Completed - Clinical trials for Early Gastric Cancer

Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation

Start date: September 2011
Phase: N/A
Study type: Observational

The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy in patients given triple therapy for Helicobacter pylori eradication with Nexium + amoxicillin (AMPC) + clarithromycin (CAM), or Nexium + AMPC + metronidazole (MNZ) in usual post-marketing use.

NCT ID: NCT01434524 Completed - Liver Cancer Clinical Trials

Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids

Start date: April 2007
Phase: N/A
Study type: Interventional

The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear. The aim of this study is to assess the impact of oral supplementation with BCAA on the prevention for the development of liver tumorigenesis in patients undergoing liver resection.